Allogene Therapeutics said its Q2 2026 business update showed further progress across its allogeneic CAR-T and cell therapy pipeline. The backdrop: FDA RMAT and

BWB News TV • 2026-08-12 20:13 UTC • By Billy Odell Tucker-Robinson

Allogene Therapeutics said its Q2 2026 business update showed further progress across its allogeneic CAR-T and cell therapy pipeline. The backdrop: FDA RMAT and Fast Track status for cema-cel in LBCL and a newly launched LBCL trial.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly